Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab
These findings could be valuable for patient counselling, though validation in a larger cohort is desired.
Authors
- Alyssa A Toorop (ORCID: https://orcid.org/0000-0002-7196-9826)
- Liza M. Y. Gelissen (ORCID: https://orcid.org/0009-0004-4864-1429)
- Eva M. M. Strijbis (ORCID: https://orcid.org/0000-0001-6705-5864)
- Zoé L. E. van Kempen (ORCID: https://orcid.org/0000-0001-9557-5381)
- Bob W. van Oosten (ORCID: https://orcid.org/0000-0003-4536-6201)
- Brigit A. de Jong (ORCID: https://orcid.org/0000-0002-7005-7008)
- Laura Hogenboom (ORCID: https://orcid.org/0009-0005-1230-1366)
- Joep Killestein (ORCID: https://orcid.org/0000-0002-6347-5957)
Institutions
- Amsterdam Neuroscience (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Journal of the Neurological Sciences
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1016/j.jns.2025.125652
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47